AbbVie Inc. demonstrated a significant financial turnaround in fiscal 2025, posting over $16.6 billion in revenue—a 10% increase year-over-year—and recovering net income to positive territory after prior losses. This rebound reflects operational leverage and strategic focus on immunology and oncology pipelines, including promising Phase 3 trial results for bispecific antibodies targeting hematologic cancers. Despite robust operating cash flow and ongoing dividends, the company faces headwinds from patent cliffs, regulatory uncertainties, and a current ratio below 1 indicating liquidity constraints. Capital allocation has balanced dividend commitments with tempered buybacks amid debt maturity considerations. Key upcoming clinical milestones will be crucial signals for sustained momentum in this competitive pharmaceutical landscape.